Approximately 40% of NSCLC harbor allele-specific loss of heterozygosity in human leukocyte antigen class I (HLA-I LOH), a genomic alteration associated with increased neoantigen burden, PD-L1 positivity, and poor clinical response to ICI (68, 69). The gene discussed is CD274; the disease is non-small cell lung carcinoma.